Loading
A UK study testing whether a breath test can tell people with stomach, gullet or liver cancer from people without.
PAN study (NCT03756597) is an observational study sponsored by Owlstone Ltd with Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK. It is a case-control study of whether Breath Biopsy can distinguish patients with and without different cancers by breath biomarkers.
The registry record, read on 29 October 2026, gives its status as completed, with 268 participants enrolled, a start on 26 September 2018 and primary completion on 2 December 2022.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/